Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing

(2016) Andrew J. Clark et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

(2014) E. Pham et al.   CLINICAL CANCER RESEARCH

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

(2014) Robert J Motzer et al.   LANCET ONCOLOGY

High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium

(2013) John D. Hainsworth et al.   Clinical Genitourinary Cancer

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

(2013) Glen J. Weiss et al.   INVESTIGATIONAL NEW DRUGS

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

(2013) S. Eliasof et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

(2012) Annamaria Rapisarda et al.   Nature Reviews Clinical Oncology

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1  in Advanced Solid Tumors

(2011) S. Kummar et al.   CLINICAL CANCER RESEARCH

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

(2011) Naomi B. Haas et al.   MEDICAL ONCOLOGY

Inhibition of Hypoxia-Inducible Factor-1α (HIF-1α) Protein Synthesis by DNA Damage Inducing Agents

(2010) Jessica Jie Wei Lou et al.   PLoS One

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

(2009) A. Rapisarda et al.   MOLECULAR CANCER THERAPEUTICS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE